Marvel Biosciences (TSXV:MRVL) Net Margin % : 0.00% (As of Jan. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Marvel Biosciences's Net Income for the three months ended in Jan. 2025 was C$-0.49 Mil. Marvel Biosciences's Revenue for the three months ended in Jan. 2025 was C$0.00 Mil. Therefore, Marvel Biosciences's net margin for the quarter that ended in Jan. 2025 was 0.00%.

The historical rank and industry rank for Marvel Biosciences's Net Margin % or its related term are showing as below:

TSXV:MRVL's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -114.45
* Ranked among companies with meaningful Net Margin % only.

Marvel Biosciences Net Margin % Historical Data

The historical data trend for Marvel Biosciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Net Margin % Chart

Marvel Biosciences Annual Data

Trend

Jul20

Jul21

Jul22

Jul23

Jul24

Net Margin %

Marvel Biosciences Quarterly Data
	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Net Margin %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Marvel Biosciences's Net Margin %

For the Biotechnology subindustry, Marvel Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marvel Biosciences's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Net Margin % falls into.

Save Embed

;

Save Embed

;

Marvel Biosciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Marvel Biosciences's Net Margin for the fiscal year that ended in Jul. 2024 is calculated as

Net Margin	=	Net Income (A: Jul. 2024 )	/	Revenue (A: Jul. 2024 )
	=	-1.65	/	0
	=	%

Marvel Biosciences's Net Margin for the quarter that ended in Jan. 2025 is calculated as

Net Margin	=	Net Income (Q: Jan. 2025 )	/	Revenue (Q: Jan. 2025 )
	=	-0.486	/	0
	=	%

Marvel Biosciences (TSXV:MRVL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Marvel Biosciences Net Margin % Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

MBCOF:USA

Address

505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2

Website

https://www.marvelbiotechnology.com

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Executives